Toxicological Research

  • 제41권2호
  • /
  • Pages.131-147
  • /
  • 2025
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

Oxidative stress and NRF2 signaling in kidney injury

  • Cherry Ng (Department of Pharmacy and BK21FOUR Advanced Program for Smart Pharma Leaders, Graduate School of The Catholic University of Korea) ;
  • Maxine Kim (Department of Pharmacy and BK21FOUR Advanced Program for Smart Pharma Leaders, Graduate School of The Catholic University of Korea) ;
  • Yanti (Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia) ;
  • Mi‑Kyoung Kwak (Department of Pharmacy and BK21FOUR Advanced Program for Smart Pharma Leaders, Graduate School of The Catholic University of Korea)
  • 투고 : 2024.09.10
  • 심사 : 2024.11.30
  • 발행 : 2025.03.15
⟨ 이전 논문 다음 논문 ⟩

초록

Oxidative stress plays a crucial role in the pathogenesis of acute kidney injury (AKI), chronic kidney disease (CKD), and the AKI-to-CKD transition. This review examines the intricate relationship between oxidative stress and kidney pathophysiology, emphasizing the potential therapeutic role of nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of cellular redox homeostasis. In diverse AKI and CKD models, diminished NRF2 activity exacerbates oxidative stress, whereas genetic and pharmacological NRF2 activation alleviates kidney damage induced by nephrotoxic agents, ischemia-reperfusion injury, fibrotic stimuli, and diabetic nephropathy. The renoprotective effects of NRF2 extend beyond antioxidant defense, encompassing its anti-inflammatory and anti-fibrotic properties. The significance of NRF2 in renal fibrosis is further underscored by its interaction with the transforming growth factor-β signaling cascade. Clinical trials using bardoxolone methyl, a potent NRF2 activator, have yielded both encouraging and challenging outcomes, illustrating the intricacy of modulating NRF2 in human subjects. In summary, this overview suggests the therapeutic potential of targeting NRF2 in kidney disorders and highlights the necessity for continued research to refine treatment approaches.

키워드

과제정보

This study was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government [MSIT; grant numbers 2022R1A2C2011866 and 2018R1A6A1A03025108]. This study was also supported by the Research Fund, 2023 of The Catholic University of Korea.

참고문헌

  1. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ (2021) Acute kidney injury. Nat Rev Dis Primers 7:52. https://doi.org/10.1038/s41572-021-00284-z
  2. Barnett LMA, Cummings BS (2018) Nephrotoxicity and renal pathophysiology: a contemporary perspective. Toxicol Sci Of J Soc Toxicol 164:379–390. https://doi.org/10.1093/toxsci/kfy159
  3. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 16:269–288. https://doi.org/10.1038/s41581-019-0248-y
  4. Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. N Engl J Med 372:1138–1149. https://doi.org/10.1056/NEJMra1300575
  5. Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-β: the master regulator of fbrosis. Nat Rev Nephrol 12:325–338. https://doi.org/10.1038/nrneph.2016.48
  6. Kishi S, Nagasu H, Kidokoro K, Kashihara N (2024) Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol 20:101–119. https://doi.org/10.1038/s41581-023-00775-0
  7. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC (2012) Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 17:311–321. https://doi.org/10.1111/j.1440-1797.2012.01572.x
  8. Forbes JM, Thorburn DR (2018) Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 14:291–312. https://doi.org/10.1038/nrneph.2018.9
  9. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins 2:2490–2518. https://doi.org/10.3390/toxins2112490
  10. Su L, Zhang J, Gomez H, Kellum JA, Peng Z (2023) Mitochondria ROS and mitophagy in acute kidney injury. Autophagy 19:401–414. https://doi.org/10.1080/15548627.2022.2084862
  11. Daehn IS, Ekperikpe US, Stadler K (2023) Redox regulation in diabetic kidney disease. Am J Physiol Renal Physiol 325:F135–F149. https://doi.org/10.1152/ajprenal.00047.2023
  12. Baird L, Yamamoto M (2020) The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol 40:00099-20. https://doi.org/10.1128/mcb.00099-20
  13. Yamamoto M, Kensler TW, Motohashi H (2018) The KEAP1-NRF2 system: a thiol-based sensor-efector apparatus for maintaining redox homeostasis. Physiol Rev 98:1169–1203. https://doi.org/10.1152/physrev.00023.2017
  14. Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218. https://doi.org/10.1016/j.tibs.2014.02.002
  15. Shaw P, Chattopadhyay A (2020) Nrf2-ARE signaling in cellular protection: mechanism of action and the regulatory mechanisms. J Cell Physiol 235:3119–3130. https://doi.org/10.1002/jcp.29219
  16. Saha S, Buttari B, Panieri E, Profumo E, Saso L (2020) An overview of Nrf2 signaling pathway and its role in infammation. Molecules (Basel, Switzerland) 25:5474. https://doi.org/10.3390/molecules25225474
  17. Stenvinkel P, Chertow GM, Devarajan P, Levin A, Andreoli SP, Bangalore S, Warady BA (2021) Chronic infammation in chronic kidney disease progression: role of Nrf2. Kidney Int Rep 6:1775–1787. https://doi.org/10.1016/j.ekir.2021.04.023
  18. Kim HJ, Sato T, Rodríguez-Iturbe B, Vaziri ND (2011) Role of intrarenal angiotensin system activation, oxidative stress, infammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther 337:583–590. https://doi.org/10.1124/jpet.110.175828
  19. Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and infammation in chronic renal failure. Am J Physiol Renal Physiol 298:F662–F671. https://doi.org/10.1152/ajprenal.00421.2009
  20. Nezu M, Souma T, Yu L, Suzuki T, Saigusa D, Ito S, Suzuki N, Yamamoto M (2017) Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. Kidney Int 91:387–401. https://doi.org/10.1016/j.kint.2016.08.023
  21. Tan RJ, Chartoumpekis DV, Rush BM, Zhou D, Fu H, Kensler TW, Liu Y (2016) Keap1 hypomorphism protects against ischemic and obstructive kidney disease. Sci Rep 6:36185. https://doi.org/10.1038/srep36185
  22. Juul-Nielsen C, Shen J, Stenvinkel P, Scholze A (2022) Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity. Nephrol Dial Transpl Of Publ Eur Dial Transpl Assoc Eur Renal Assoc 37:904–916. https://doi.org/10.1093/ndt/gfab031
  23. Liu Y, Uruno A, Saito R, Matsukawa N, Hishinuma E, Saigusa D, Liu H, Yamamoto M (2022) Nrf2 defciency deteriorates diabetic kidney disease in Akita model mice. Redox Biol 58:102525. https://doi.org/10.1016/j.redox.2022.102525
  24. Tan SM, Sharma A, Stefanovic N, Yuen DY, Karagiannis TC, Meyer C, Ward KW, Cooper ME, de Haan JB (2014) Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes 63:3091–3103. https://doi.org/10.2337/db13-1743
  25. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59:850–860. https://doi.org/10.2337/db09-1342
  26. Kong W, Fu J, Liu N, Jiao C, Guo G, Luan J, Wang H, Yao L, Wang L, Yamamoto M, Pi J, Zhou H (2018) Nrf2 defciency promotes the progression from acute tubular damage to chronic renal fbrosis following unilateral ureteral obstruction. Nephrol Dial Transpl Of Publ Eur Dial Transpl Assoc Eur Renal Assoc 33:771–783. https://doi.org/10.1093/ndt/gfx299
  27. Ryoo IG, Ha H, Kwak MK (2014) Inhibitory role of the KEAP1-NRF2 pathway in TGFβ1-stimulated renal epithelial transition to fbroblastic cells: a modulatory efect on SMAD signaling. PLoS One 9:e93265. https://doi.org/10.1371/journal.pone.0093265
  28. Bakin AV, Stourman NV, Sekhar KR, Rinehart C, Yan X, Meredith MJ, Arteaga CL, Freeman ML (2005) Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding Phase II detoxifying proteins. Free Radic Biol Med 38:375–387. https://doi.org/10.1016/j.freeradbiomed.2004.10.033
  29. Okita Y, Kamoshida A, Suzuki H, Itoh K, Motohashi H, Igarashi K, Yamamoto M, Ogami T, Koinuma D, Kato M (2013) Transforming growth factor-β induces transcription factors MafK and Bach1 to suppress expression of the heme oxygenase-1 gene. J Biol Chem 288:20658–20667. https://doi.org/10.1074/jbc.M113.450478
  30. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, ChristSchmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492–2503. https://doi.org/10.1056/NEJMoa1306033
  31. Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T (2020) Randomized clinical trial on the efect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI Study). Kidney Int Rep 5:879–890. https://doi.org/10.1016/j.ekir.2020.03.030
  32. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z (2014) Regulated cell death in AKI. J Am Soc Nephrol 25:2689–2701. https://doi.org/10.1681/asn.2014030262
  33. Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, Latchem S, Lewington A, Milford DV, Ostermann M (2015) The defnition of acute kidney injury and its use in practice. Kidney Int 87:62–73. https://doi.org/10.1038/ki.2014.328
  34. Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu KD, Prowle JR, Shaw AD, Srisawat N, Cheung M, Jadoul M, Winkelmayer WC, Kellum JA (2020) Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 98:294–309. https://doi.org/10.1016/j.kint.2020.04.020
  35. Levey AS (2022) Defning AKD: the spectrum of AKI, AKD, and CKD. Nephron 146:302–305. https://doi.org/10.1159/000516647
  36. Coca SG, Yalavarthy R, Concato J, Parikh CR (2008) Biomarkers for the diagnosis and risk stratifcation of acute kidney injury: a systematic review. Kidney Int 73:1008–1016. https://doi.org/10.1038/sj.ki.5002729
  37. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66:1115–1122. https://doi.org/10.1111/j.1523-1755.2004.00861.x
  38. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237–244. https://doi.org/10.1046/j.1523-1755.2002.00433.x
  39. Al-Bataineh MM, Kinlough CL, Mi Z, Jackson EK, Mutchler SM, Emlet DR, Kellum JA, Hughey RP (2021) KIM-1-mediated anti-infammatory activity is preserved by MUC1 induction in the proximal tubule during ischemia-reperfusion injury. Am J Physiol Renal Physiol 321:F135–F148. https://doi.org/10.1152/ajprenal.00127.2021
  40. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL (2004) Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43:405–414. https://doi.org/10.1053/j.ajkd.2003.10.040
  41. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmelé T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (London, England) 17:R25. https://doi.org/10.1186/cc12503
  42. Perazella MA (2009) Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol: CJASN 4:1275–1283. https://doi.org/10.2215/cjn.02050309
  43. Karasawa T, Steyger PS (2015) An integrated view of cisplatininduced nephrotoxicity and ototoxicity. Toxicol Lett 237:219–227. https://doi.org/10.1016/j.toxlet.2015.06.012
  44. Deng F, Zheng X, Sharma I, Dai Y, Wang Y, Kanwar YS (2021) Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism. Am J Physiol Renal Physiol 320:F578–F595. https://doi.org/10.1152/ajprenal.00016.2021
  45. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol: CJASN 11:1173–1179. https://doi.org/10.2215/cjn.08070715
  46. Akilesh S, Juaire N, Dufeld JS, Smith KD (2014) Chronic Ifosfamide toxicity: kidney pathology and pathophysiology. Am J Kidney Dis 63:843–850. https://doi.org/10.1053/j.ajkd.2013.11.028
  47. Balakumar P, Rohilla A, Thangathirupathi A (2010) Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res 62:179–186. https://doi.org/10.1016/j.phrs.2010.04.004
  48. Filippone EJ, Kraft WK, Farber JL (2017) The nephrotoxicity of vancomycin. Clin Pharmacol Ther 102:459–469. https://doi.org/10.1002/cpt.726
  49. Chawla LS, Eggers PW, Star RA, Kimmel PL (2014) Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371:58–66. https://doi.org/10.1056/NEJMra1214243
  50. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA (2010) Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 55:S23–S33. https://doi.org/10.1053/j.ajkd.2009.09.035
  51. Glassock RJ, Warnock DG, Delanaye P (2017) The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol 13:104–114. https://doi.org/10.1038/nrneph.2016.163
  52. Tejeswini Sen T, Kale A, Lech M, Anders HJ, Gaikwad AB (2023) Promising novel therapeutic targets for kidney disease: emphasis on kidney-specific proteins. Drug Discov Today 28:103466. https://doi.org/10.1016/j.drudis.2022.103466
  53. Huang R, Fu P, Ma L (2023) Kidney fbrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther 8:129. https://doi.org/10.1038/s41392-023-01379-7
  54. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. Lancet (London, England) 382:260–272. https://doi.org/10.1016/s0140-6736(13)60687-x
  55. Hultström M (2012) Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens 30:1087–1091. https://doi.org/10.1097/HJH.0b013e328352b89a
  56. He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, Sun L, Peng Y, Liu F, Venkatachalam MA, Dong Z (2017) AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int 92:1071–1083. https://doi.org/10.1016/j.kint.2017.06.030
  57. Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura T, Humphreys BD, Bonventre JV (2012) Targeted proximal tubule injury triggers interstitial fbrosis and glomerulosclerosis. Kidney Int 82:172–183. https://doi.org/10.1038/ki.2012.20
  58. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK (2015) Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 26:1765–1776. https://doi.org/10.1681/asn.2015010006
  59. Zhang T, Widdop RE, Ricardo SD (2024) Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers. Am J Physiol Renal Physiol 327:F788–F805. https://doi.org/10.1152/ajprenal.00184.2024
  60. Agarwal A, Dong Z, Harris R, Murray P, Parikh SM, Rosner MH, Kellum JA, Ronco C (2016) Cellular and molecular mechanisms of AKI. J Am Soc Nephrol 27:1288–1299. https://doi.org/10.1681/asn.2015070740
  61. Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. J Clin Investig 121:4210–4221. https://doi.org/10.1172/jci45161
  62. Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z (2018) Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol 315:F1098–F1106. https://doi.org/10.1152/ajprenal.00199.2018
  63. Fu Y, Xiang Y, Wei Q, Ilatovskaya D, Dong Z (2024) Rodent models of AKI and AKI-CKD transition: an update in 2024. Am J Physiol Renal Physiol 326:F563–F583. https://doi.org/10.1152/ajprenal.00402.2023
  64. Sharp CN, Doll MA, Megyesi J, Oropilla GB, Beverly LJ, Siskind LJ (2018) Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol Renal Physiol 315:F161–F172. https://doi.org/10.1152/ajprenal.00636.2017
  65. Jadot I, Colombaro V, Martin B, Habsch I, Botton O, Nortier J, Declèves AE, Caron N (2017) Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. PLoS One 12:e0183604. https://doi.org/10.1371/journal.pone.0183604
  66. Yan LJ (2021) Folic acid-induced animal model of kidney disease. Anim Models Exp Med 4:329–342. https://doi.org/10.1002/ame2.12194
  67. Mapuskar KA, Wen H, Holanda DG, Rastogi P, Steinbach E, Han R, Coleman MC, Attanasio M, Riley DP, Spitz DR, Allen BG, Zepeda-Orozco D (2019) Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol 20:98–106. https://doi.org/10.1016/j.redox.2018.09.020
  68. Sahu BD, Mahesh Kumar J, Sistla R (2015) Baicalein, a biofavonoid, prevents cisplatin-induced acute kidney injury by upregulating antioxidant defenses and down-regulating the MAPKs and NF-κB pathways. PLoS One 10:e0134139. https://doi.org/10.1371/journal.pone.0134139
  69. Tang C, Livingston MJ, Safrstein R, Dong Z (2023) Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol 19:53–72. https://doi.org/10.1038/s41581-022-00631-7
  70. Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol Of J Ges fur Toxikol Pathol 61:223–242. https://doi.org/10.1016/j.etp.2008.09.003
  71. King DW, Smith MA (2004) Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro Int J Publ Assoc BIBRA 18:797–803. https://doi.org/10.1016/j.tiv.2004.03.013
  72. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Ogino T, Inoue M, Okada S, Kinoshita H (2003) Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radical Res 37:373–379. https://doi.org/10.1080/1071576031000061002
  73. Hall AM, Rhodes GJ, Sandoval RM, Corridon PR, Molitoris BA (2013) In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury. Kidney Int 83:72–83. https://doi.org/10.1038/ki.2012.328
  74. Carcy R, Cougnon M, Poet M, Durandy M, Sicard A, Counillon L, Blondeau N, Hauet T, Tauc M, Pisani DF (2021) Targeting oxidative stress, a crucial challenge in renal transplantation outcome. Free Radic Biol Med 169:258–270. https://doi.org/10.1016/j.freeradbiomed.2021.04.023
  75. Aranda-Rivera AK, Cruz-Gregorio A, Aparicio-Trejo OE, Ortega-Lozano AJ, Pedraza-Chaverri J (2021) Redox signaling pathways in unilateral ureteral obstruction (UUO)-induced renal fbrosis. Free Radic Biol Med 172:65–81. https://doi.org/10.1016/j.freeradbiomed.2021.05.034
  76. Kawada N, Moriyama T, Ando A, Fukunaga M, Miyata T, Kurokawa K, Imai E, Hori M (1999) Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 56:1004–1013. https://doi.org/10.1046/j.1523-1755.1999.00612.x
  77. Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354. https://doi.org/10.1074/jbc.R400019200
  78. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790. https://doi.org/10.1038/35008121
  79. Cho SJ, Roman G, Yeboah F, Konishi Y (2007) The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem 14:1653–1671. https://doi.org/10.2174/092986707780830989
  80. Scivittaro V, Ganz MB, Weiss MF (2000) AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278:F676–F683. https://doi.org/10.1152/ajprenal.2000.278.4.F676
  81. Ighodaro OM (2018) Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother 108:656–662. https://doi.org/10.1016/j.biopha.2018.09.058
  82. Vodošek Hojs N, Bevc S, Ekart R, Hojs R (2020) Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxidants (Basel, Switzerland) 9:925. https://doi.org/10.3390/antiox9100925
  83. Araujo M, Wilcox CS (2014) Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal 20:74–101. https://doi.org/10.1089/ars.2013.5259
  84. Adler S, Huang H (2004) Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 287:F907–F913. https://doi.org/10.1152/ajprenal.00060.2004
  85. Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS (2005) Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol 288:H22–H28. https://doi.org/10.1152/ajpheart.00626.2004
  86. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Investig 97:1916–1923. https://doi.org/10.1172/jci118623
  87. Zhang Y, Murugesan P, Huang K, Cai H (2020) NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol 17:170–194. https://doi.org/10.1038/s41569-019-0260-8
  88. Yıldırım E, İpek E, Bavunoğlu I, Yıldırım N, Cengiz M, Yavuzer S, Yavuzer H, Erman H, Uzun H (2017) The impact of protein oxidation on sustained and white coat hypertension. Anatol J Cardiol 17:210–216. https://doi.org/10.14744/AnatolJCardiol.2016.7174
  89. Kishi H, Kishi T, Folkers K (1975) Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 12:533–540
  90. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24:10941–10953. https://doi.org/10.1128/mcb.24.24.10941-10953.2004
  91. Suzuki T, Muramatsu A, Saito R, Iso T, Shibata T, Kuwata K, Kawaguchi SI, Iwawaki T, Adachi S, Suda H, Morita M, Uchida K, Baird L, Yamamoto M (2019) Molecular mechanism of cellular oxidative stress sensing by Keap1. Cell Rep 28:746–758. e4. https://doi.org/10.1016/j.celrep.2019.06.047
  92. Itoh K, Igarashi K, Hayashi N, Nishizawa M, Yamamoto M (1995) Cloning and characterization of a novel erythroid cellderived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol 15:4184–4193. https://doi.org/10.1128/mcb.15.8.4184
  93. Otsuki A, Yamamoto M (2020) Cis-element architecture of Nrf2-sMaf heterodimer binding sites and its relation to diseases. Arch Pharmacal Res 43:275–285. https://doi.org/10.1007/s12272-019-01193-2
  94. Wild AC, Mulcahy RT (2000) Regulation of gamma-glutamylcysteine synthetase subunit gene expression: insights into transcriptional control of antioxidant defenses. Free Radical Res 32:281–301. https://doi.org/10.1080/10715760000300291
  95. Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, Tamba M, Itoh K, Yamamoto M, Bannai S (2002) Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 277:44765–44771. https://doi.org/10.1074/jbc.M208704200
  96. Banning A, Deubel S, Kluth D, Zhou Z, Brigelius-Flohé R (2005) The GI-GPx gene is a target for Nrf2. Mol Cell Biol 25:4914–4923. https://doi.org/10.1128/mcb.25.12.4914-4923.2005
  97. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S (2002) Identifcation of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62:5196–5203
  98. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identifcation of novel gene clusters for cell survival. J Biol Chem 278:8135–8145. https://doi.org/10.1074/jbc.M211898200
  99. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313–322. https://doi.org/10.1006/bbrc.1997.6943
  100. Lever JM, Boddu R, George JF, Agarwal A (2016) Heme Oxygenase-1 in kidney health and disease. Antioxid Redox Signal 25:165–183. https://doi.org/10.1089/ars.2016.6659
  101. Dulak J, Deshane J, Jozkowicz A, Agarwal A (2008) Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 117:231–241. https://doi.org/10.1161/circulationaha.107.698316
  102. Shelton LM, Lister A, Walsh J, Jenkins RE, Wong MH, Rowe C, Ricci E, Ressel L, Fang Y, Demougin P, Vukojevic V, O'Neill PM, Goldring CE, Kitteringham NR, Park BK, Odermatt A, Copple IM (2015) Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney Int 88:1261–1273. https://doi.org/10.1038/ki.2015.286
  103. Lawrence T (2009) The nuclear factor NF-kappaB pathway in infammation. Cold Spring Harb Perspect Biol 1:a001651. https://doi.org/10.1101/cshperspect.a001651
  104. Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in infammation. Nat Rev Immunol 8:837–848. https://doi.org/10.1038/nri2423
  105. Wardyn JD, Ponsford AH, Sanderson CM (2015) Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans 43:621–626. https://doi.org/10.1042/bst20150014
  106. Ganesh Yerra V, Negi G, Sharma SS, Kumar A (2013) Potential therapeutic efects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy. Redox Biol 1:394–397. https://doi.org/10.1016/j.redox.2013.07.005
  107. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, Biswal S (2006) Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Investig 116:984–995. https://doi.org/10.1172/jci25790
  108. Liu GH, Qu J, Shen X (2008) NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochem Biophys Acta 1783:713–727. https://doi.org/10.1016/j.bbamcr.2008.01.002
  109. Kim SW, Lee HK, Shin JH, Lee JK (2013) Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving It from p65. Free Radical Biol Med 65:468–476. https://doi.org/10.1016/j.freeradbiomed.2013.07.028
  110. Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi S (2001) Nrf2-defcient female mice develop lupus-like autoimmune nephritis. Kidney Int 60:1343–1353. https://doi.org/10.1046/j.1523-1755.2001.00939.x
  111. Noel S, Arend LJ, Bandapalle S, Reddy SP, Rabb H (2016) Kidney epithelium specifc deletion of kelch-like ECH-associated protein 1 (Keap1) causes hydronephrosis in mice. BMC Nephrol 17:110. https://doi.org/10.1186/s12882-016-0310-y
  112. Suzuki T, Seki S, Hiramoto K, Naganuma E, Kobayashi EH, Yamaoka A, Baird L, Takahashi N, Sato H, Yamamoto M (2017) Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus. Nat Commun 8:14577. https://doi.org/10.1038/ncomms14577
  113. Cetin R, Devrim E, Kiliçoğlu B, Avci A, Candir O, Durak I (2006) Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol: JAT 26:42–46. https://doi.org/10.1002/jat.1103
  114. Singh I, Gulati S, Orak JK, Singh AK (1993) Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem 125:97–104. https://doi.org/10.1007/bf00936438
  115. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND (2013) Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and infammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transpl Of Publ Eur Dial Transpl Assoc Eur Renal Assoc 28:2038–2045. https://doi.org/10.1093/ndt/gft022
  116. Qiao P, Sun Y, Wang Y, Lin S, An Y, Wang L, Liu J, Huang Y, Yang B, Zhou H (2023) Activation of NRF2 signaling pathway delays the progression of hyperuricemic nephropathy by reducing oxidative stress. Antioxidants (Basel, Switzerland) 12:1022. https://doi.org/10.3390/antiox12051022
  117. Velmurugan GV, Sundaresan NR, Gupta MP, White C (2013) Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res 100:143–150. https://doi.org/10.1093/cvr/cvt125
  118. Kim BH, Lee ES, Choi R, Nawaboot J, Lee MY, Lee EY, Kim HS, Chung CH (2016) Protective efects of curcumin on renal oxidative stress and lipid metabolism in a rat model of Type 2 diabetic nephropathy. Yonsei Med J 57:664–673. https://doi.org/10.3349/ymj.2016.57.3.664
  119. Mohan T, Narasimhan KKS, Ravi DB, Velusamy P, Chandrasekar N, Chakrapani LN, Srinivasan A, Karthikeyan P, Kannan P, Tamilarasan B, Johnson T, Kalaiselvan P, Periandavan K (2020) Role of Nrf2 dysfunction in the pathogenesis of diabetic nephropathy: therapeutic prospect of epigallocatechin-3-gallate. Free Radic Biol Med 160:227–238. https://doi.org/10.1016/j.freeradbiomed.2020.07.037
  120. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP, Rabb H (2009) Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 76:277–285. https://doi.org/10.1038/ki.2009.157
  121. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335:2–12. https://doi.org/10.1124/jpet.110.170084
  122. Chen C, Han X, Wang G, Liu D, Bao L, Jiao C, Luan J, Hou Y, Xu Y, Wang H, Zhang Q, Zhou H, Fu J, Pi J (2021) Nrf2 defciency aggravates the kidney injury induced by subacute cadmium exposure in mice. Arch Toxicol 95:883–893. https://doi.org/10.1007/s00204-020-02964-3
  123. Park HM, Cho JM, Lee HR, Shim GS, Kwak MK (2008) Renal protection by 3H–1,2-dithiole-3-thione against cisplatin through the Nrf2-antioxidant pathway. Biochem Pharmacol 76:597–607. https://doi.org/10.1016/j.bcp.2008.06.021
  124. Trujillo J, Chirino YI, Molina-Jijón E, Andérica-Romero AC, Tapia E, Pedraza-Chaverrí J (2013) Renoprotective efect of the antioxidant curcumin: recent fndings. Redox Biol 1:448–456. https://doi.org/10.1016/j.redox.2013.09.003
  125. Guerrero-Beltrán CE, Calderón-Oliver M, Tapia E, Medina-Campos ON, Sánchez-González DJ, Martínez-Martínez CM, OrtizVega KM, Franco M, Pedraza-Chaverri J (2010) Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicol Lett 192:278–285. https://doi.org/10.1016/j.toxlet.2009.11.007
  126. Mohajeri M, Rezaee M, Sahebkar A (2017) Cadmium-induced toxicity is rescued by curcumin: a review. BioFactors (Oxford, England) 43:645–661. https://doi.org/10.1002/biof.1376
  127. Liu Z, Shi B, Wang Y, Xu Q, Gao H, Ma J, Jiang X, Yu W (2022) Curcumin alleviates aristolochic acid nephropathy based on SIRT1/Nrf2/HO-1 signaling pathway. Toxicology 479:153297. https://doi.org/10.1016/j.tox.2022.153297
  128. Hamdy S, Elshopakey GE, Risha EF, Rezk S, Ateya AI, Abdelhamid FM (2024) Curcumin mitigates gentamicin induced-renal and cardiac toxicity via modulation of Keap1/Nrf2, NF-κB/iNOS and Bcl-2/BAX pathways. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 183:114323. https://doi.org/10.1016/j.fct.2023.114323
  129. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA, Grossman E, Chen J, Zhou XJ, Hartono J, Winterberg P, Chen B, Agarwal A, Lu CY (2011) Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. Am J Physiol Renal Physiol 300:F1180–F1192. https://doi.org/10.1152/ajprenal.00353.2010
  130. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW, Park BH (2008) Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 75:2214–2223. https://doi.org/10.1016/j.bcp.2008.02.029
  131. Bondi CD, Rush BM, Hartman HL, Wang J, Al-Bataineh MM, Hughey RP, Tan RJ (2022) Suppression of NRF2 activity by HIF-1α promotes fbrosis after ischemic acute kidney injury. Antioxidants (Basel, Switzerland) 11:1810. https://doi.org/10.3390/antiox11091810
  132. Tanase DM, Gosav EM, Anton MI, Floria M, Seritean Isac PN, Hurjui LL, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C (2022) Oxidative stress and NRF2/KEAP1/ARE pathway in Diabetic Kidney Disease (DKD): new perspectives. Biomolecules 12:1227. https://doi.org/10.3390/biom12091227
  133. Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimohata H, Itoh K, Takahashi S, Yamamoto M (2008) Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-defcient mice. Genes Cells Devoted Mol Cell Mech 13:1159–1170. https://doi.org/10.1111/j.1365-2443.2008.01234.x
  134. Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M (2023) Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: therapeutic targeting, challenges and future prospective. Biochim Biophys Acta 1869:166714. https://doi.org/10.1016/j.bbadis.2023.166714
  135. Guerrero-Hue M, Rayego-Mateos S, Vázquez-Carballo C, Palomino-Antolín A, García-Caballero C, Opazo-Rios L, MorgadoPascual JL, Herencia C, Mas S, Ortiz A, Rubio-Navarro A, Egea J, Villalba JM, Egido J, Moreno JA (2020) Protective role of Nrf2 in renal disease. Antioxidants (Basel, Switzerland) 10:39. https://doi.org/10.3390/antiox10010039
  136. Chin M, Lee CY, Chuang JC, Bumeister R, Wigley WC, Sonis ST, Ward KW, Meyer C (2013) Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efcacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol 304:F1438–F1446. https://doi.org/10.1152/ajprenal.00387.2012
  137. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huf JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327–336. https://doi.org/10.1056/NEJMoa1105351
  138. Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T (2023) Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transp Of Publ Eur Dial Transpl Assoc Eur Renal Assoc 38:1204–1216. https://doi.org/10.1093/ndt/gfac242
  139. Aranda-Rivera AK, Cruz-Gregorio A, Amador-Martínez I, Medina-Campos ON, Garcia-Garcia M, Bernabe-Yepes B, LeónContreras JC, Hernández-Pando R, Aparicio-Trejo OE, SánchezLozada LG, Tapia E, Pedraza-Chaverri J (2024) Sulforaphane protects from kidney damage during the release of unilateral ureteral obstruction (RUUO) by activating nuclear factor erythroid 2-related factor 2 (Nrf2): role of antioxidant, anti-infammatory, and antiapoptotic mechanisms. Free Radic Biol Med 212:49–64. https://doi.org/10.1016/j.freeradbiomed.2023.12.022
  140. Oh CJ, Kim JY, Choi YK, Kim HJ, Jeong JY, Bae KH, Park KG, Lee IK (2012) Dimethylfumarate attenuates renal fbrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. PLoS One 7:e45870. https://doi.org/10.1371/journal.pone.0045870
  141. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, Kim DD, Kim SG, Kang KW, Ku SK, Kensler TW, Kwak MK (2010) The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fbrosis. Free Radic Biol Med 48:1051–1063. https://doi.org/10.1016/j.freeradbiomed.2010.01.021
  142. Hong YA, Lim JH, Kim MY, Kim EN, Koh ES, Shin SJ, Choi BS, Park CW, Chang YS, Chung S (2014) Delayed treatment with oleanolic acid attenuates tubulointerstitial fbrosis in chronic cyclosporine nephropathy through Nrf2/HO-1 signaling. J Transl Med 12:50. https://doi.org/10.1186/1479-5876-12-50
  143. Zhao YY, Wang HL, Cheng XL, Wei F, Bai X, Lin RC, Vaziri ND (2015) Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, infammation, fbrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep 5:12936. https://doi.org/10.1038/srep12936
  144. Song MK, Lee JH, Ryoo IG, Lee SH, Ku SK, Kwak MK (2019) Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation. Free Radic Biol Med 138:33–42. https://doi.org/10.1016/j.freeradbiomed.2019.04.033
  145. Nagasu H, Sogawa Y, Kidokoro K, Itano S, Yamamoto T, Satoh M, Sasaki T, Suzuki T, Yamamoto M, Wigley WC, Proksch JW, Meyer CJ, Kashihara N (2019) Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function. FASEB J Of Publ Fed Am Soc Exp Biol 33:12253–12263. https://doi.org/10.1096/f.201900217R
  146. Liu RM, Desai LP (2015) Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fbrosis. Redox Biol 6:565–577. https://doi.org/10.1016/j.redox.2015.09.009
  147. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL (2010) NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofbroblasts. J Am Soc Nephrol 21:93–102. https://doi.org/10.1681/asn.2009020146
  148. Yoon YS, Lee JH, Hwang SC, Choi KS, Yoon G (2005) TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene 24:1895–1903. https://doi.org/10.1038/sj.onc.1208262
  149. Liu RM, Vayalil PK, Ballinger C, Dickinson DA, Huang WT, Wang S, Kavanagh TJ, Matthews QL, Postlethwait EM (2012) Transforming growth factor β suppresses glutamate-cysteine ligase gene expression and induces oxidative stress in a lung fbrosis model. Free Radic Biol Med 53:554–563. https://doi.org/10.1016/j.freeradbiomed.2012.05.016
  150. Arsalane K, Dubois CM, Muanza T, Bégin R, Boudreau F, Asselin C, Cantin AM (1997) Transforming growth factor-beta1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional efect on the GSH rate-limiting enzyme gamma-glutamylcysteine synthetase. Am J Respir Cell Mol Biol 17:599–607. https://doi.org/10.1165/ajrcmb.17.5.2833
  151. Jardine H, MacNee W, Donaldson K, Rahman I (2002) Molecular mechanism of transforming growth factor (TGF)-beta1-induced glutathione depletion in alveolar epithelial cells. Involvement of AP-1/ARE and Fra-1. J Biol Chem 277:21158–21166. https://doi.org/10.1074/jbc.M112145200
  152. Michaeloudes C, Sukkar MB, Khorasani NM, Bhavsar PK, Chung KF (2011) TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 300:L295–L304. https://doi.org/10.1152/ajplung.00134.2010
  153. Islam KN, Kayanoki Y, Kaneto H, Suzuki K, Asahi M, Fujii J, Taniguchi N (1997) TGF-beta1 triggers oxidative modifcations and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic Biol Med 22:1007–1017. https://doi.org/10.1016/s0891-5849(96)00493-5
  154. Kim SK, Bae GS, Bae T, Ku SK, Choi BH, Kwak MK (2024) Renal microRNA-144-3p is associated with transforming growth factor-β1-induced oxidative stress and fbrosis by suppressing the NRF2 pathway in hypertensive diabetic kidney disease. Free Radic Biol Med 225:546–559. https://doi.org/10.1016/j.freeradbiomed.2024.10.286
  155. Sun C, Li S, Li D (2016) Sulforaphane mitigates muscle fbrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling. J Appl Physiol (Bethesda, Md: 1985) 120:377–390. https://doi.org/10.1152/japplphysiol.00721.2015
  156. Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, Datta PK, Freeman ML (2010) Increased cell migration and plasticity in Nrf2-defcient cancer cell lines. Oncogene 29:3703–3714. https://doi.org/10.1038/onc.2010.118
  157. Li Z, Deng H, Guo X, Yan S, Lu C, Zhao Z, Feng X, Li Q, Wang J, Zeng J, Ma X (2022) Efective dose/duration of natural favonoid quercetin for treatment of diabetic nephropathy: a systematic review and meta-analysis of rodent data. Phytomedicine Int J Phytother Phytopharmacol 105:154348. https://doi.org/10.1016/j.phymed.2022.154348
  158. Shi X, Jiang W, Yang X, Ma H, Wang Z, Ai Q, Dong Y, Zhang Y, Shi Y (2023) Aucubin inhibits hepatic stellate cell activation through stimulating Nrf2/Smad7 axis. Eur J Pharmacol 957:176002. https://doi.org/10.1016/j.ejphar.2023.176002
  159. Wang L, He C (2022) Nrf2-mediated anti-infammatory polarization of macrophages as therapeutic targets for osteoarthritis. Front Immunol 13:967193. https://doi.org/10.3389/fmmu.2022.967193
  160. Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M (2018) Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction. Cell Commun Signal 16:54. https://doi.org/10.1186/s12964-018-0262-x
  161. Qin T, Du R, Huang F, Yin S, Yang J, Qin S, Cao W (2016) Sinomenine activation of Nrf2 signaling prevents hyperactive infammation and kidney injury in a mouse model of obstructive nephropathy. Free Radic Biol Med 92:90–99. https://doi.org/10.1016/j.freeradbiomed.2016.01.011
  162. Feng J, Liu Z, Chen H, Zhang M, Ma X, Han Q, Lu D, Wang C (2021) Protective efect of cynaroside on sepsis-induced multiple organ injury through Nrf2/HO-1-dependent macrophage polarization. Eur J Pharmacol 911:174522. https://doi.org/10.1016/j.ejphar.2021.174522
  163. Noel S, Martina MN, Bandapalle S, Racusen LC, Potteti HR, Hamad AR, Reddy SP, Rabb H (2015) T Lymphocyte-specifc activation of Nrf2 protects from AKI. J Am Soc Nephrol 26:2989–3000. https://doi.org/10.1681/asn.2014100978
  164. Warady BA, Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Kashtan CE, Knebelmann B, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Rheault MN, Silva AL, Stenvinkel P, Torra R, Chertow GM (2022) Efects of bardoxolone methyl in Alport syndrome. Clin J Am Soc Nephrol: CJASN 17:1763–1774. https://doi.org/10.2215/cjn.02400222
  165. Quinlan C, Jayasinghe K (2022) Bardoxolone methyl for Alport syndrome: opportunities and challenges. Clin J Am Soc Nephrol: CJASN 17:1713–1715. https://doi.org/10.2215/cjn.12491022
  166. Rush BM, Bondi CD, Stocker SD, Barry KM, Small SA, Ong J, Jobbagy S, Stolz DB, Bastacky SI, Chartoumpekis DV, Kensler TW, Tan RJ (2021) Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int 99:102–116. https://doi.org/10.1016/j.kint.2020.07.036
  167. Zhao S, Lo CS, Miyata KN, Ghosh A, Zhao XP, Chenier I, Cailhier JF, Ethier J, Lattouf JB, Filep JG, Ingelfnger JR, Zhang SL, Chan JSD (2021) Overexpression of Nrf2 in renal proximal tubular cells stimulates sodium-glucose cotransporter 2 expression and exacerbates dysglycemia and kidney injury in diabetic mice. Diabetes 70:1388–1403. https://doi.org/10.2337/db20-1126
  168. Su K, Zhao SL, Yang WX, Lo CS, Chenier I, Liao MC, Pang YC, Peng JZ, Miyata KN, Cailhier JF, Ethier J, Lattouf JB, Filep JG, Ingelfnger JR, Zhang SL, Chan JSD (2023) NRF2 defciency attenuates diabetic kidney disease in Db/Db mice via down-regulation of angiotensinogen, SGLT2, CD36, and FABP4 expression and lipid accumulation in renal proximal tubular cells. Antioxidants (Basel, Switzerland) 12:1715. https://doi.org/10.3390/antiox12091715
  169. Vallon V, Verma S (2021) Efects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83:503–528. https://doi.org/10.1146/annurev-physiol-031620-095920
  170. Hirashima Y, Nakano T, Torisu K, Aihara S, Wakisaka M, Kitazono T (2024) SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis. Sci Rep 14:20386. https://doi.org/10.1038/s41598-024-71416-0
  171. Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S, Root DE, Tamayo P, Tsherniak A, Cheng SC, Tabak B, Jacobsen A, Hakimi AA, Schultz N, Ciriello G, Sander C, Hsieh JJ, Kaelin WG Jr (2013) SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 24:738–750. https://doi.org/10.1016/j.ccr.2013.10.025
  172. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12:213–223. https://doi.org/10.1038/ncb2021
  173. Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ (2016) Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep 14:2476–2489. https://doi.org/10.1016/j.celrep.2016.02.024
  174. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molinié V, Richard S, Tan PH, Teh BT, Furge KA (2011) An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20:511–523. https://doi.org/10.1016/j.ccr.2011.08.024
  175. Clerici S, Boletta A (2020) Role of the KEAP1-NRF2 axis in renal cell carcinoma. Cancers 12:3458. https://doi.org/10.3390/cancers12113458
  176. Rinaldi Tosi ME, Bocanegra V, Manucha W, Gil Lorenzo A, Vallés PG (2011) The Nrf2-Keap1 cellular defense pathway and heat shock protein 70 (Hsp70) response. Role in protection against oxidative stress in early neonatal unilateral ureteral obstruction (UUO). Cell Stress Chaperones 16:57–68. https://doi.org/10.1007/s12192-010-0221-y